Clinical Trials Logo

Significant Bleeding Risk clinical trials

View clinical trials related to Significant Bleeding Risk.

Filter by:
  • None
  • Page 1

NCT ID: NCT06429787 Not yet recruiting - Clinical trials for Significant Bleeding Risk

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Start date: June 30, 2024
Phase:
Study type: Observational

Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

NCT ID: NCT02740335 Completed - Clinical trials for Significant Bleeding Risk

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Start date: June 8, 2017
Phase: Phase 3
Study type: Interventional

To demonstrate that the efficacy of OCTAPLEX as a reversal agent in patients under Vitamin K Antagonist (VKA) therapy with the need for urgent surgery with significant bleeding risk is clinically non-inferior to that Beriplex® P/N (Kcentra).